Related Experiment Video
Updated: May 15, 2025
Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity
Published on: April 11, 2019
Plasmapheresis for Facilitating Readministration of Rituximab After Paradoxical Exacerbation in Pemphigus Vulgaris: A
Mohammad Reza Pourani1,2, Sayyed Mojtaba Nekooghadam3, Fatemeh Samadi1
1Skin Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
Rare reports of post-rituximab exacerbation of pemphigus vulgaris (PV) have been published, with some therapeutic protocols proposed for managing this condition. A 40-year-old female with PV experienced an exacerbation of mucocutaneous lesions following rituximab administration. She failed to respond to conventional immunosuppressive agents, intravenous immunoglobulin, and ocrelizumab, so plasmapheresis was administered. Then, further doses of rituximab were prescribed, and mucocutaneous lesions improved significantly. We propose plasmapheresis as a possible treatment for post-rituximab PV exacerbation, also noting that subsequent doses of rituximab can be safe and effective.
Rare reports of post-rituximab exacerbation of pemphigus vulgaris (PV) have been published, with some therapeutic protocols proposed for managing this condition. A 40-year-old female with PV experienced an exacerbation of mucocutaneous lesions following rituximab administration. She failed to respond to conventional immunosuppressive agents, intravenous immunoglobulin, and ocrelizumab, so plasmapheresis was administered. Then, further doses of rituximab were prescribed, and mucocutaneous lesions improved significantly. We propose plasmapheresis as a possible treatment for post-rituximab PV exacerbation, also noting that subsequent doses of rituximab can be safe and effective.
